In 2020, AstraZeneca paid a total of 39 billion U.S. dollars in upfront cash and equity for merger and acquisition deals, while Gilead paid nearly 28 billion U.S. dollars. This statistic illustrates the top buyers in biopharma therapeutics and platforms, diagnostics, and medtech (also digital health) merger and acquisition deals worldwide in 2020, by upfront cash and equity paid.
Leading buyers in biopharma, diagnostics, and medtech M&A deals worldwide in 2020, by upfront cash and equity paid*
(in billion U.S. dollars)
Adjust the presentation of the statistic and data points.
Share the statistic on social media channels or embed the statistic in your
website using "Embed Code", where available.
Cite this statistic and select one of the following formats: APA, Chicago, Harvard, MLA & Bluebook.
Print the statistic including description and metadata.
Chart type
Leading buyers in biopharma, diagnostics, and medtech M&A deals worldwide in 2020, by upfront cash and equity paid*
Share this statistic
You have no right to use this feature.
Make sure to contact us if you are interested in scientific citation.
You can upgrade your account to enable this functionality for all statistics.
This feature is not available with your current account.Request access
Learn more about how Statista can support your business.
DealForma. (February 17, 2021). Leading buyers in biopharma, diagnostics, and medtech M&A deals worldwide in 2020, by upfront cash and equity paid* (in billion U.S. dollars) [Graph]. In Statista. Retrieved December 19, 2024, from https://www.statista.com/statistics/1240320/top-buyers-biopharma-ma-deals-by-upfront-cash-and-equity-paid/
DealForma. "Leading buyers in biopharma, diagnostics, and medtech M&A deals worldwide in 2020, by upfront cash and equity paid* (in billion U.S. dollars)." Chart. February 17, 2021. Statista. Accessed December 19, 2024. https://www.statista.com/statistics/1240320/top-buyers-biopharma-ma-deals-by-upfront-cash-and-equity-paid/
DealForma. (2021). Leading buyers in biopharma, diagnostics, and medtech M&A deals worldwide in 2020, by upfront cash and equity paid* (in billion U.S. dollars). Statista. Statista Inc.. Accessed: December 19, 2024. https://www.statista.com/statistics/1240320/top-buyers-biopharma-ma-deals-by-upfront-cash-and-equity-paid/
DealForma. "Leading Buyers in Biopharma, Diagnostics, and Medtech M&a Deals Worldwide in 2020, by Upfront Cash and Equity Paid* (in Billion U.S. Dollars)." Statista, Statista Inc., 17 Feb 2021, https://www.statista.com/statistics/1240320/top-buyers-biopharma-ma-deals-by-upfront-cash-and-equity-paid/
DealForma, Leading buyers in biopharma, diagnostics, and medtech M&A deals worldwide in 2020, by upfront cash and equity paid* (in billion U.S. dollars) Statista, https://www.statista.com/statistics/1240320/top-buyers-biopharma-ma-deals-by-upfront-cash-and-equity-paid/ (last visited December 19, 2024)
Leading buyers in biopharma, diagnostics, and medtech M&A deals worldwide in 2020, by upfront cash and equity paid* (in billion U.S. dollars) [Graph], DealForma, February 17, 2021. [Online]. Available: https://www.statista.com/statistics/1240320/top-buyers-biopharma-ma-deals-by-upfront-cash-and-equity-paid/
Profit from additional features with an Employee Account
Please create an employee account to be able to mark statistics as favorites.
Then you can access your favorite statistics via the star in the header.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.